1. Introduction
1.1. Research Methodology
1.2. Research Scope
1.2.1. Analysis by Company
1.2.2. Analysis by Phase
1.2.3. By Molecule Type
1.2.4. By region
2. Disease Overview
2.1.1. Introduction
2.1.2. Classification
2.1.3. Symptoms
2.1.4. Causes
2.1.5. Diagnoses
2.1.6. Treatment
2.1.7. Epidemiology
3. Executive Summary
4. Market Dynamics
4.1. Drivers
4.2. Restraints
4.3. Opportunities
5. Pipeline Analysis/Outlook
5.1. Analysis by Company
5.2. Analysis by Phase
5.2.1. Phase of Development
5.2.1.1. Introduction
5.2.1.1.1. Drug Profiling
• Drug Name
• Generic Name
• Synonyms
• Company
• Collaborator
• Route of administration
• Target
• Mechanism of Action
• Technology
• Molecule type
• CAS Number
• Weight
• Chemical Formula
• IUPAC name
• ATC code
5.2.1.1.2. Strategic Developments
5.2.1.1.3. Clinical trials
5.2.1.1.4. Clinical trial results
5.2.1.1.5. Patents
5.2.1.1.6. Technology
5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar graph)
5.3. By Molecule type
5.4. Analysis by Region
6. Company profiling
6.1. Savant HWP, Inc.
6.1.1. Introduction
6.1.2. Financials
6.1.3. Products and Services
6.1.4. SWOT
6.1.5. Recent Development
6.2. Addexx Therapeutics
6.2.1. Introduction
6.2.2. Financials
6.2.3. Products and Services
6.2.4. SWOT
6.2.5. Recent Development
6.3. Opiant Pharmaceuticals, Inc
6.3.1. Introduction
6.3.2. Financials
6.3.3. Products and Services
6.3.4. SWOT
6.3.5. Recent Development
6.4. Omeros Corp
6.4.1. Introduction
6.4.2. Financials
6.4.3. Products and Services
6.4.4. SWOT
6.4.5. Recent Development
6.5. Adial Pharmaceuticals
6.5.1. Introduction
6.5.2. Financials
6.5.3. Products and Services
6.5.4. SWOT
6.5.5. Recent Development
6.6. Montisera Ltd
6.6.1. Introduction
6.6.2. Financials
6.6.3. Products and Services
6.6.4. SWOT
6.6.5. Recent Development
6.7. Ethypharm SA
6.7.1. Introduction
6.7.2. Financials
6.7.3. Products and Services
6.7.4. SWOT
6.7.5. Recent Development
6.8. Medicinova
6.8.1. Introduction
6.8.2. Financials
6.8.3. Products and Services
6.8.4. SWOT
6.8.5. Recent Development
6.9. Amygdala Neurosciences, Inc.
6.9.1. Introduction
6.9.2. Financials
6.9.3. Products and Services
6.9.4. SWOT
6.9.5. Recent Development
6.10. Curemark LLC
6.10.1. Introduction
6.10.2. Financials
6.10.3. Products and Services
6.10.4. SWOT
6.10.5. Recent Development
6.11. Kinnov Therapeutics
6.11.1. Introduction
6.11.2. Financials
6.11.3. Products and Services
6.11.4. SWOT
6.11.5. Recent Development
6.12. BioCorRx, Inc
6.12.1. Introduction
6.12.2. Financials
6.12.3. Products and Services
6.12.4. SWOT
6.12.5. Recent Development
6.13. Corcept Therapeutics Inc
6.13.1. Introduction
6.13.2. Financials
6.13.3. Products and Services
6.13.4. SWOT
6.13.5. Recent Development
6.14. Bionex Pharmaceuticals LLC
6.14.1. Introduction
6.14.2. Financials
6.14.3. Products and Services
6.14.4. SWOT
6.14.5. Recent Development
6.15. Bioprojet SCR
6.15.1. Introduction
6.15.2. Financials
6.15.3. Products and Services
6.15.4. SWOT
6.15.5. Recent Development
6.16. Chronos Therapeutics Ltd
6.16.1. Introduction
6.16.2. Financials
6.16.3. Products and Services
6.16.4. SWOT
6.16.5. Recent Development
6.17. Lohocla Research Corp
6.17.1. Introduction
6.17.2. Financials
6.17.3. Products and Services
6.17.4. SWOT
6.17.5. Recent Developments
6.18. Lohocla Research Corp
6.18.1. Introduction
6.18.2. Financials
6.18.3. Products and Services
6.18.4. SWOT
6.18.5. Recent Developments
6.19. Silence Therapeutics Plc
6.19.1. Introduction
6.19.2. Financials
6.19.3. Products and Services
6.19.4. SWOT
6.19.5. Recent Developments
6.20. Syntropharma Limited
6.20.1. Introduction
6.20.2. Financials
6.20.3. Products and Services
6.20.4. SWOT
6.20.5. Recent Developments
6.21. Laboratorio Farmaceutico Ct S.r.l.
6.21.1. Introduction
6.21.2. Financials
6.21.3. Products and Services
6.21.4. SWOT
6.21.5. Recent Development
6.22. Pop Test Oncology LLC
6.22.1. Introduction
6.22.2. Financials
6.22.3. Products and Services
6.22.4. SWOT
6.22.5. Recent Development
List of Tables
List of Figures